Economie Impact of Treatment of HIV-Positive Pregnant Women and Their Newborns with Zidovudine Implications for HIV Screening

JAMA

Volumn 276, Issue 2, 1996, Pages 132-138

  Mauskopf, Josephine A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ADULT; ARTICLE; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN INFECTION; PREGNANCY; PRIORITY JOURNAL; SCREENING; VIRUS TRANSMISSION;

EID: 0029683043     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.2.132     Document Type: Article

References (42)

1. Centers for Disease Control and Prevention. A'ational HIV Serosurceillance Summary: Results Tlmtugh 1932. Atlanta, Ga: US Dept of Health and Human Services, Public Health Service; 1994:rvol 3.
2. Yogev R, Connor E, eds. Management of HIV Infection in Infants and Children. St Louis, Mo: Mosby-Year Book; 1992:8-19.
3. The European Collaborative Study. Natural history of vertically acquired human immunodeficiency virus-1 infection. Pediatrics. 1994;94:815-819.
4. Frederick T, Mascola L, Eller A, et al. Progression of human immunodeficiency virus disease among infants and children infected perinatally with human immunodeficiency virus or through neonatal blood transfusion. Pediatr Infect Dus J. 1994;13:1091-1097.
5. Stein Z. HIV prevention: an update on the status of methods women can use. Am J Public Health. 1993;83:1379-1382.
6. Connor EM, Sperling RS, Gelber R, et al, for the Pédiatrie AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;231:1173-1180.
7. Centers for Disease Control and Prevention. Recommendations for the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1994;43(RR11):1-20.
8. Garrett HM, ed. 1994 Red Book. Montvale, NJ: Medical Economics Data; August 1994:48.
9. Parrott RH. Childhood human immunodeficiency virus infection: the spectrum of costs. J Acquir Immune Defic Syndr. 1991;4:122-129.
10. Hegarty JD, Abrams EJ, Hutchinson VE, et al. The medical care costs of human immunodeficiency virus-infected children in Harlem. JAMA. 1988;60:1901-1909.
11. Hsia D, Fleishman J, East J, Hellinger F. Pédiatrie human immunodeficiency virus infection. Arch Pediatr Adolesc Med. 1995;149:489-496.
12. Andrulis D, Weslowski V, Hintz E, Spolarich A. Comparisons of hospital care for patients with AIDS and other HIV-related conditions. JAMA. 1992;267:2482-2486.
13. Statistical Abstract of the United States: 1995. 115th ed. Washington, DC: US Bureau of the Census; 1995:494,Table 762.
14. Barnhart H, Caldwell B, Thomas P, et al. HIV progression in perinatally infected children. Presented at the Second Conference on Retroviruses and Opportunistic Infections; February 1, 1995; Washington, DC. Abstract 575.
15. Havens PL, Cuene BE, Hand JR. Lifetime cost for children with HIV infection. Presented at the Third Conference on Antiretrovirals and Opportunistic Infections; January 30,1996; Washington, DC. Abstract 272.
16. Gwinn M, Wasser S, Fleming P, Karon J, Peterson L. Increasing prevalence of HIV infection among childbearing women, United States, 1989-1991. In: Program and abstracts of the Ninth International Conference on AIDS; June 6June 11,1993; Berlin, Germany. Abstract No. PO-C16-2990.
17. Hardy IM, ed. HIV Screening of Pregnant Women and Neicborns. Washington, DC: Committee on Prenatal and Newborn Screening for HIV Infection, Institute of Medicine, National Academy Press; 1991.
18. Ventura SJ, Martin JA, Taffei SM, et al. Advance report of final natality statistics, 1993. Vital Health Stat 3. Hyattsville, Md: National Center for Health Statistics; 1995; No.44(suppl 1995): Table 33.
19. Lindsay MK, Feng TI, Peterson HB, et al. Routine human immunodeficiency virus infection screening in unregistered and registered inner-city parturients. Obstet Gynecol. 1991;77:599-603.
20. Barbacci MB, Dalabetta GA, Repke JT, et al. Human immunodeficiency virus infection in women attending an inner-city prenatal clinic. Sex Transm Dis. 1990;17:122-126.
21. Barbacci M, Repke JT, Chaisson RE. Routine prenatal screening for HIV infection. Lancet. 1991; 337:709-711.
22. Fehrs LJ, Hul D, Kerndt PR, et al. Targeted HIV screening at a Los Angeles prenatal/family planning health center. Am J Public Health. 1991;21:019-622.
23. Lindsay MK, Adefris W, Peterson HB, et al. Determinants of acceptance of routine voluntary human immunodeficiency virus testing in an inner-city prenatal patient population. Obstet Gynecol. 1989;78:678-680.
24. Cozen W, Mascola L, Enguidanos R, et al. Screening for HIV and hepatitis B virus in Los Angeles County prenatal clinics: a demonstration project. J Acqitir Immune Defic Syndr. 1993;6:95-98.
25. Hedlund K, Spencer J, Schalla W, et al. Estimated public costs of HIV counseling and testing, USA. In: Program and abstracts of the Sixth International Conference on AIDS; June 20-24,1990; San Francisco, Calif. Abstract FD835.
26. Phillips KA, Löwe RA, Kahn JG, et al. The costeffectiveness of HIV testing of physicians and dentists in the United States. JAMA. 1994;271:851-858.
27. Lurie P, Avins AL, Phillips KA, et al. The costeffectiveness of voluntary counseling and testing of hospital inpatients for HIV infection. JAMA. 1994;272:1832-1838.
28. Brown AE, Burke DS. Cost of HIV testing in the US Army. N Engl J Med. 1995;232:963.
29. McCarthy BD, Wong JB, Munoz A, et al. Who should be screened for HIV infection? Arch Intern Med. 1993;153:1107-1116.
30. Brandeau ML, Owens DK, Sox CH, et al. Screening women of childbearing age for human immunodeficiency virus. Archlntern Med. 1992;152:2229-2237.
31. Turaock BJ, Kelly CJ. Mandatory premarital testing for human immunodeficiency virus: the Illinois experience. JAMA. 1989;261:3415-3418.
32. Weber B, Hess G, Koberstein R, Doerr HW. Evaluation of the automated 'Enzymen-Test Anti HIV-1+2 and "Enzymen-Test Anti HIV-1/2 selective' for the combined detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies. J Viral Methods. 1993;44251-260.
33. Gwinn M, Redus MA, Granade TC, et al. HIV-1 sérologie test results for one million newborn driedblood specimens. J Acquir Immune Defic Syndr. 1992;5:505-512.
34. Holtgrave DR, Valdiserri RO, Gerber AR, et al. Human immunodeficiency virus counseling, testing, referral, and partner notification services: a cost benefit analysis. Arch Intern Med, 1993;153:1225-1230.
35. MacDonald KL, Jackson JB, Bowman RJ, et al. Performance charcteristics of sérologie tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Ann Intern Med. 1989;110:617-621.
36. Burke DS, Brundage JF, Redfield RR, et al. Measurement of false-positive rates in a screening program for human immunodeficiency virus infections. N Engl J Med. 1988;219:961-964.
37. Hellinger F. The lifetime cost of treating a person with HIV. JAMA. 1993;270:474-478.
38. Faden R, Gielen A, Kass N, O'Campo P, Sheon A. Reproductive preferences of pregnant women under shifting probabilities of vertical HIV transmission. Worn Health Issues. 1993;3216-222.
39. Selwyn P, Carter R, Shoenbaum E, Robertson V, Klein R, Rogers M. Knowledge of HIV antibody status and decisions to continue of terminate pregnancy among intravenous drug users. JAMA. 1989; 261:3567-3571.
40. Johnstone F, Brettle R, MacCallum L, Mok J, Peutherer J, Burns S. Women's knowledge of their HIV antibody status: its effect on their decision whether to continue their pregnancy. BMJ. 1990: 300:23-24.
41. Bloom DE, Glied S. Benefits and costs of HIV testing. Science. 1991;252:1798-1804.
42. Chavey WE, Cantor SB, Clover RD, et al. Costeffectiveness analysis of screening health care workers for HIV. J Fam Pract. 1994;38:249-257.